KRAS and non-small cell lung carcinoma: On the other hand, a subgroup analysis of the IMpower150 trial revealed that the trial arm, ABCP regimen, demonstrated superior antitumor effects compared to the control arm in KRAS-mutant NSCLC with STK11 or KEAP1 mutations (57).